Back to top
more

Dr. Reddys Laboratories (RDY)

(Delayed Data from NYSE)

$71.49 USD

71.49
130,426

-0.66 (-0.91%)

Updated Apr 23, 2024 04:00 PM ET

After-Market: $71.52 +0.03 (0.04%) 4:36 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (179 out of 252)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for RDY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Dr Reddy's Laboratories Ltd falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Assets          
Cash & Equivalents -99,999 767 610 490 356
Receivables NA 882 880 679 667
Notes Receivable NA 0 0 0 0
Inventories NA 592 671 621 465
Other Current Assets NA 277 236 238 241
Total Current Assets NA 2,518 2,397 2,027 1,729
Net Property & Equipment NA 809 819 781 694
Investments & Advances NA 65 105 114 41
Other Non-Current Assets NA 0 1 2 23
Deferred Charges NA 88 108 145 162
Intangibles NA 427 417 549 420
Deposits & Other Assets NA 10 12 11 11
Total Assets NA 3,916 3,860 3,630 3,081
Liabilities & Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Notes Payable NA 0 0 0 0
Accounts Payable NA 322 337 325 221
Current Portion Long-Term Debt NA 148 370 328 276
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 26 21 19 8
Other Current Liabilities NA 548 510 468 461
Total Current Liabilities NA 1,044 1,239 1,140 966
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 10 1 5 4
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 16 76 86 17
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 36 33 33 38
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,106 1,348 1,264 1,025
Shareholders Equity 3/31/2024 3/31/2023 3/31/2022 3/31/2021 3/31/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 10 11 11 11
Capital Surplus NA 118 122 122 113
Retained Earnings NA 2,623 2,316 2,133 1,913
Other Equity NA 75 82 127 31
Treasury Stock NA 15 21 27 13
Total Shareholder's Equity NA 2,810 2,511 2,366 2,056
Total Liabilities & Shareholder's Equity NA 3,916 3,860 3,630 3,081
Total Common Equity 0 2,810 2,511 2,366 2,056
Shares Outstanding 166.80 166.50 166.40 166.20 165.70
Book Value Per Share 0.00 16.88 15.09 14.24 12.41

Fiscal Year End for Dr Reddy's Laboratories Ltd falls in the month of March.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 877 827 756 767
Receivables NA 943 839 939 882
Notes Receivable NA 0 0 0 0
Inventories NA 731 681 639 592
Other Current Assets NA 318 274 228 277
Total Current Assets NA 2,867 2,620 2,562 2,518
Net Property & Equipment NA 875 848 819 809
Investments & Advances NA 100 71 60 65
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 131 130 116 88
Intangibles NA 496 497 516 427
Deposits & Other Assets NA 14 10 10 10
Total Assets NA 4,482 4,178 4,084 3,916
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 374 367 337 322
Current Portion Long-Term Debt NA 164 86 93 148
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable NA 50 48 54 26
Other Current Liabilities NA 536 512 501 548
Total Current Liabilities NA 1,125 1,013 984 1,044
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 12 1 8 10
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 74 73 60 16
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 44 42 36
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 1,262 1,131 1,094 1,106
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 10 10 10 10
Capital Surplus NA 129 128 120 118
Retained Earnings NA 3,030 2,867 2,803 2,623
Other Equity NA 62 53 71 75
Treasury Stock NA 12 12 14 15
Total Shareholder's Equity NA 3,220 3,047 2,990 2,810
Total Liabilities & Shareholder's Equity NA 4,482 4,178 4,084 3,916
Total Common Equity 0 3,220 3,047 2,990 2,810
Shares Outstanding 166.80 166.80 166.80 166.60 166.50
Book Value Per Share 0.00 19.30 18.27 17.95 16.88